Nektar Therapeutics
NKTR
$68.67
+5.91%
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunomodulatory medicines for autoimmune diseases and cancer. It distinguishes itself through a pipeline of novel immunomodulatory agents, including rezpegaldesleukin for autoimmune conditions and NKTR-255 for oncology, positioning it as a specialized player in immunotherapy. The current investor narrative centers on a dramatic turnaround driven by promising late-stage trial results for its alopecia treatment, which reversed previous clinical setbacks and reignited optimism about the company's pipeline potential. This catalyst has fueled a massive stock rally, but debate persists around the sustainability of growth given the company's ongoing losses and reliance on clinical milestones.…
NKTR
Nektar Therapeutics
$68.67
NKTR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Nektar Therapeutics's 12-month outlook, with a consensus price target around $153.25 and implied upside of +123.2% versus the current price.
Average Target
$153.25
0 analysts
Implied Upside
+123.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $192
Analyst target range
Analyst coverage is limited, with only 4 analysts providing estimates. The consensus recommendation is Buy, with all recent ratings from firms like Citigroup, B. Riley, HC Wainwright, and BTIG maintaining Buy actions. The average estimated EPS is -$8.02, with a range from -$9.20 to -$3.80, reflecting high uncertainty. The average estimated revenue is $199.2 million, with a low of $118.6 million and high of $221.7 million. The implied upside or downside cannot be calculated directly without target prices, but the consensus EPS suggests analysts expect continued losses. The limited coverage implies Nektar is a small-cap biotech with less institutional attention, which can lead to higher volatility and less efficient price discovery. The wide range in estimates (EPS from -$9.20 to -$3.80) signals high uncertainty about the pipeline's commercial potential and timeline to profitability.
Drowning in data?
Find the real signal!
NKTR Technical Analysis
Nektar Therapeutics has experienced a dramatic uptrend over the past year, with a 1-year price change of +180.3%, significantly outperforming the S&P 500's +20.6%. The current price of $70.36 sits at 64.6% of its 52-week range ($21.02 to $109.00), indicating the stock is in the upper half but not yet at its peak, suggesting room for further upside but also potential resistance near the highs. This positioning reflects strong momentum but also a level where profit-taking could emerge. Short-term momentum shows a mixed picture: the 1-month change is +23.9%, indicating accelerating recent strength, while the 3-month change is -9.2%, signaling a pullback from the April highs. This divergence suggests the stock experienced a sharp rally in early 2026, followed by a correction, and is now recovering. The 1-month relative strength of +19.8% versus the S&P 500 confirms recent outperformance, but the 3-month relative strength of -20.3% highlights the earlier underperformance. The 52-week low of $21.02 provides strong support, while the 52-week high of $109.00 is the key resistance level. A breakout above $109 would signal a resumption of the uptrend, while a breakdown below $21 would indicate a reversal. The beta of 1.137 implies the stock is 13.7% more volatile than the market, meaning it amplifies market moves, which is important for risk management.
Beta
1.14
1.14x market volatility
Max Drawdown
-46.5%
Largest decline past year
52-Week Range
$21-$109
Price range past year
Annual Return
+177.0%
Cumulative gain past year
| Period | NKTR Return | S&P 500 |
|---|---|---|
| 1m | +12.6% | +0.2% |
| 3m | -26.3% | +5.2% |
| 6m | +88.0% | +8.6% |
| 1y | +177.0% | +19.0% |
| ytd | +58.2% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NKTR Fundamental Analysis
Revenue has been declining, with the most recent quarterly revenue of $21.8 million in Q4 2025 representing a 25.3% year-over-year decrease from $29.2 million in Q4 2024. The multi-quarter trend shows revenue falling from $29.2 million (Q4 2024) to $10.5 million (Q1 2025) before recovering to $21.8 million, indicating lumpiness likely due to royalty revenue. The company's revenue is heavily dependent on non-cash royalty revenue from the sale of future royalties, which introduces volatility. This declining trend raises concerns about the company's ability to generate sustainable top-line growth without approved products. Nektar remains unprofitable, with a net loss of -$36.1 million in Q4 2025, though this improved from -$50.9 million in Q1 2025. Gross margin is 100% due to zero cost of revenue, but operating margin is deeply negative at -87.5% in Q4 2025, reflecting high R&D and SG&A costs relative to revenue. The net margin of -165.4% indicates that losses far exceed revenue, though this is typical for clinical-stage biotechs. The trajectory shows narrowing losses from -$50.9 million in Q1 2025 to -$36.1 million in Q4 2025, suggesting cost control improvements. The balance sheet shows a debt-to-equity ratio of 1.66, indicating moderate leverage, and a current ratio of 4.97, implying strong short-term liquidity. However, free cash flow is deeply negative at -$208.7 million over the trailing twelve months, and the company has been relying on equity issuance ($38.7 million in Q4 2025) to fund operations. ROE is -182.6%, reflecting severe losses relative to shareholder equity, which is a red flag for financial sustainability.
Quarterly Revenue
$21807000.0B
2025-12
Revenue YoY Growth
-25.3%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$-208682000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NKTR Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 12.9x, while the forward PS ratio is not directly provided but can be inferred from estimated revenue. The high PS ratio reflects the market's pricing of future growth potential from the pipeline, but it also indicates significant risk given the lack of profitability. Compared to the biotechnology industry average PS ratio (which typically ranges from 5-10x for clinical-stage firms), Nektar's 12.9x represents a premium of approximately 29-58%, suggesting the market is pricing in above-average expectations for pipeline success. This premium may be justified by the recent positive trial results, but it leaves little room for error. Historically, Nektar's PS ratio has fluctuated widely, from as low as 4.5x in Q4 2023 to as high as 153x in Q1 2021. The current 12.9x is near the lower end of its historical range, indicating that despite the recent rally, the stock is not excessively valued compared to its own history. This could imply that the market remains cautious about the company's ability to commercialize its pipeline, or that the recent surge has only partially reversed previous declines.
PE
-4.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.2x
Enterprise Value Multiple
